Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1/2 multicenter trial

Blood. 2020 Jan 16;135(3):227-229. doi: 10.1182/blood.2019000358.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Female
  • Follow-Up Studies
  • Hematologic Diseases / pathology
  • Hematologic Diseases / therapy*
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Male
  • Middle Aged
  • Prognosis
  • Receptors, Fc / therapeutic use*
  • Recombinant Fusion Proteins / therapeutic use*
  • Survival Rate
  • Thrombocytopenia / drug therapy*
  • Thrombocytopenia / etiology
  • Thrombocytopenia / pathology
  • Thrombopoietin / therapeutic use*

Substances

  • Receptors, Fc
  • Recombinant Fusion Proteins
  • Thrombopoietin
  • romiplostim